AFT signs North American licensing deal for Pascomer topical treatment

AFT signs North American licensing deal for Pascomer topical treatment
Paul McBeth
By Paul McBeth July 5 (BusinessDesk) - AFT Pharmaceuticals is eyeing a US$10 million payment from a North America licensing deal but is keeping its earnings guidance unchanged for now.  The maker of Maxigesic painkillers reached the licensing and development agreement with US-based Timber Pharmaceuticals for its Pascomer drug, which treats skin lesions known as facial angiofibromas associated with the genetic disorder, tuberous sclerosis.  Timber will cover the cost of two clinical trials involving 120 patients, with the results due ne...

More Services

Latest cap raise values Sharesies at $750m
Markets

Latest cap raise values Sharesies at $750m

In its eighth raise since 2017, Sharesies values its shares at $205 apiece.

Pattrick Smellie 10 Oct 2025
Two MC partners quit for specialist firm
Services

Two MC partners quit for specialist firm

Cuncannon now has a broader commercial offering. 

Staff reporters 06 Oct 2025
DB Breweries appoints new MD
Retail

DB Breweries appoints new MD

Peter Hart returns to NZ.

Victoria Young 01 Oct 2025
2degrees earnings show cash momentum
Services

2degrees earnings show cash momentum

Non-cash costs mask strong operating earnings and cashflow.

Pattrick Smellie 24 Sep 2025